Abstract:Introduction: Obesity is known to reduce efficacy for cancer treatment patients and is thought to modulate the tumor microenvironment and glucose metabolism. In this study, we aim to quantify obesity-induced differences in the breast cancer tumor microenvironment with positron emission tomography (PET) imaging of hypoxia, glucose metabolism, and granzyme B. These experiments are testing the hypothesis that tumors in obese mice have increased glucose metabolism and hypoxia, measured by [18F]F-fluorodeoxyglucose (FDG) and [18F]F-fluoromisonidazole (FMISO) uptake. We also hypothesize that immunotherapy (IMT) increases immune activation, as measured by [68Ga]Ga-Granzyme B peptide (GZP), and that obese mice will respond less to immunotherapy than lean mice. Methods: C57/Bl6 mice were placed on a high-fat diet (HFD) with 60% kcal fat (n=18) or low-fat diet (LFD) composed of 10% kcal fat (n=18) to induce obesity. Blood serum was collected for analysis of cholesterol levels prior to tumor implantation. Body weight and food intake were measured weekly. 14 weeks after initiating each diet, 5x105 E0771 cells were implanted into the 3rd mammary fat pad and allowed to grow to 50-150mm3. Tumor-bearing mice were imaged with [18F]F-FDG and [18F]F-FMISO PET to measure glucose metabolism and hypoxia, respectively prior to treatment. Following imaging, mice began treatment with either saline (n=6/diet) or checkpoint blockade IMT with 200 ug anti-PD-1 and 100 ug anti-CTLA-4 (n=12/diet). After 3 doses of IMT, mice were imaged with [68Ga]Ga-GZP PET to measure immune activation. Tumor volume measurements and treatment administration occurred every 3 days. Metrics of standardized uptake value (SUV) including mean, max, and peak were quantified from imaging data. A one-way independent ANOVA or independent t-test was used to compare differences between groups. Results: HFD-fed mice had significantly increased body weight (p<0.0001) and serum cholesterol (p=0.005) compared to LFD-fed mice. SUVmean for tumor hypoxia (p=0.003) and glucose metabolism (p=0.02) were significantly increased at baseline in HFD-fed mice compared to LFD-fed mice. IMT increases immune activation for both LFD-fed (p=0.009) and HFD-fed mice (p=0.05). IMT treatment significantly reduces tumor burden for LFD mice (p<0.0001), but not HFD mice (p=0.096). Conclusions: Obesity plays a role in the reduction of the effectiveness of immunotherapy. At baseline, tumors of obese mice have increased tumor glucose metabolism and hypoxia. Although immunotherapy increases immune activation, this is not sufficient to reduce tumor burden or improve overall survival. Understanding obesity-induced differences in tumor biology may provide imaging-directed treatment decision making. Citation Format: Shannon E. Lynch, Corinne Crawford, Addison Hunt, Luke Sligh, Benjamin M. Larimer, Suzanne E. Lapi, Anna G. Sorace. PET imaging to characterize the tumor microenvironment in a breast cancer model of obesity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4154.

Anti PD-1 treatment increases [18F]FDG uptake by cancer cells in a mouse B16F10 melanoma model

Influence on [18F]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor

The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1

Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer

PD1 blockade alters cell-cycle distribution and affects 3′-deoxy-3′-[18F]fluorothymidine uptake in a mouse CT26 tumor model

Advantages of FBPA PET in evaluating early response of anti-PD-1 immunotherapy in B16F10 melanoma-bearing mice: Comparison to FDG PET

Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis

FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma

Role of GLUT-1 in the Upregulation of PD-L1 Expression after Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer

Targeting the ROS/PI3K/AKT/HIF‐1α/HK2 Axis of Breast Cancer Cells: Combined Administration of Polydatin and 2‐Deoxy‐d‐glucose

Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors

Blockade of glucose-6-phosphate dehydrogenase induces immunogenic cell death and accelerates immunotherapy

Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapy

Abstract 4154: PET imaging to characterize the tumor microenvironment in a breast cancer model of obesity

Thiazolidinedione enhances the efficacy of anti-PD-1 monoclonal antibody in murine melanoma

A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect

A Preliminary Study of the Effect of the Degree of Drug Resistance of Pancreatic Cancer on F-18-FDG Uptake Value and Its Mechanism

Abstract 2746: PET-CT/FACS Platform to Detect the Biodistribution of Radioisotope 89zr PD-1 Inhibitor in Syngeneic Tumor Models

Alteration of Hypoxia and Glucose Metabolism Measured by 18F-Fmiso and 18F-Fdg Micropet/Ct Imaging During Anti-Angiogenic Therapy

Prognostic Significance of 18F-FDG PET/CT and Tumor Metabolic Changes in Patients With Pancreatic Ductal Adenocarcinoma

Glucose-6-phosphatase Expression-Mediated [18F]FDG Efflux in Murine Inflammation and Cancer Models